» Articles » PMID: 29872711

Identification and Targeting of an FGFR Fusion in a Pediatric Thalamic "central Oligodendroglioma"

Overview
Publisher Springer Nature
Specialty Oncology
Date 2018 Jun 7
PMID 29872711
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Approximately 1-5% of pediatric intracranial tumors originate in the thalamus. While great strides have been made to identify consistent molecular markers in adult oligodendrogliomas, such as the 1p/19q co-deletion, it is widely recognized that pediatric oligodendrogliomas have a vastly different molecular make-up. While pediatric thalamic or "central oligodendrogliomas" are histologically similar to peripheral pediatric oligodendrogliomas, they are behaviorally distinct and likely represent a cohesive, but entirely different entity. We describe a case of a 10-year-old girl who was diagnosed with an anaplastic glioma with features consistent with the aggressive entity often diagnosed as central or thalamic oligodendroglioma. We performed whole-exome (paired tumor and germline DNA) and transcriptome (tumor RNA) sequencing, which demonstrated an fusion. We describe this fusion and our rationale for pursuing personalized, targeted therapy for the patient's tumor that may potentially play a role in the treatment of similar cases.

Citing Articles

Long-term outcomes of symptomatic optic pathway glioma: 32-year experience at a single Western Australian tertiary pediatric oncology center.

Rajagopal R, Khan M, Lethbridge R, Lee G, Lee S, Dyke J Front Oncol. 2023; 13:1157909.

PMID: 37519788 PMC: 10379632. DOI: 10.3389/fonc.2023.1157909.


Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers.

Brown L, Ekert P, Fleuren E Oncogene. 2023; 42(23):1875-1888.

PMID: 37130917 PMC: 10244177. DOI: 10.1038/s41388-023-02705-7.


Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.

Metais A, Tauziede-Espariat A, Garcia J, Appay R, Uro-Coste E, Meyronet D Acta Neuropathol Commun. 2023; 11(1):14.

PMID: 36647073 PMC: 9843943. DOI: 10.1186/s40478-023-01506-z.


FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.

Gott H, Uhl E Int J Mol Sci. 2022; 23(15).

PMID: 35955806 PMC: 9369421. DOI: 10.3390/ijms23158675.


The oncogenic fusion landscape in pediatric CNS neoplasms.

Roosen M, Ode Z, Bunt J, Kool M Acta Neuropathol. 2022; 143(4):427-451.

PMID: 35169893 PMC: 8960661. DOI: 10.1007/s00401-022-02405-8.


References
1.
Hyder D, Sung L, Pollack I, Gilles F, Yates A, Davis R . Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience. J Neurooncol. 2007; 83(1):1-8. DOI: 10.1007/s11060-006-9299-6. View

2.
Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

3.
Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y . Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015; 47(5):458-68. DOI: 10.1038/ng.3273. View

4.
Nickel R, Daves M, Keller F . Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib. Pediatr Blood Cancer. 2015; 62(11):2050-1. DOI: 10.1002/pbc.25551. View

5.
Fernandez C, Maues de Paula A, Colin C, Quilichini B, Bouvier-Labit C, Girard N . Thalamic gliomas in children: an extensive clinical, neuroradiological and pathological study of 14 cases. Childs Nerv Syst. 2006; 22(12):1603-10. DOI: 10.1007/s00381-006-0184-6. View